Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions (Q42933541)

11 November 2017

title

Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions (English)

1 reference

11 November 2017

1 reference

1 reference

Bonnie B Dean

1

1 reference

11 November 2017

Hsing-Ting Yu

2

1 reference

11 November 2017

Jay P Bae

3

1 reference

11 November 2017

Suzanne Fiske

4

1 reference

11 November 2017

Eric Meadows

5

1 reference

11 November 2017

Yan Xiong

6

1 reference

11 November 2017

Matthew F Emons

7

1 reference

11 November 2017

publication date

1 September 2010

1 reference

American Journal of Health-System Pharmacy

11 November 2017

published in

1 reference

11 November 2017

volume

67

1 reference

11 November 2017

issue

17

1 reference

11 November 2017

page(s)

1430-1437

1 reference

Management of patients undergoing percutaneous coronary revascularization

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

National efforts to improve door-to-balloon time results from the Door-to-Balloon Alliance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Loading, pretreatment, and interindividual variability issues with clopidogrel dosing

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Early versus delayed, provisional eptifibatide in acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Variable platelet response to aspirin and clopidogrel in atherothrombotic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100008

31 March 2020

Identifiers

DOI

10.2146/AJHP100008

1 reference

11 November 2017

1 reference